Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
16
08
2022
pubmed:
31
8
2022
medline:
12
10
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
A limited number of studies have addressed the protective duration of coronavirus disease 2019 (COVID-19) vaccines following primary and booster doses in Saudi Arabia. Therefore, this study aimed to evaluate the protective duration of primary and booster doses of BNT162b2 and ChAdOx1 COVID-19 vaccine batches in Saudi Arabia. A cross-sectional study was conducted from 1 January to 31 December, 2021. The study included 53,354 people infected with severe acute respiratory syndrome coronavirus-2 2 weeks or more after receiving at least a primary vaccination of either the ChAdOx1 or BNT162b2 vaccine. The total median protective duration of both primary COVID-19 vaccinations was 134 days. Heterologous primary vaccination (ChAdOx1 followed by BNT162b2) showed a significantly higher median protective duration of 142 days. The results show that the total median protective duration of the first booster doses of COVID-19 vaccines was 57 days. ChAdOx1 batch code C1 was found to have the most extended protective duration of 173 days (range 163-192 days). The current study revealed that the median protective duration of ChAdOx1 and BNT162b2 COVID-19 primary vaccination regimens administered in Saudi Arabia in 2021 was 134 days and that heterologous primary vaccination (ChAdOx1→BNT162b2) exhibited a significantly higher protective duration than other vaccination regimens.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
A limited number of studies have addressed the protective duration of coronavirus disease 2019 (COVID-19) vaccines following primary and booster doses in Saudi Arabia. Therefore, this study aimed to evaluate the protective duration of primary and booster doses of BNT162b2 and ChAdOx1 COVID-19 vaccine batches in Saudi Arabia.
METHODS
METHODS
A cross-sectional study was conducted from 1 January to 31 December, 2021. The study included 53,354 people infected with severe acute respiratory syndrome coronavirus-2 2 weeks or more after receiving at least a primary vaccination of either the ChAdOx1 or BNT162b2 vaccine.
RESULTS
RESULTS
The total median protective duration of both primary COVID-19 vaccinations was 134 days. Heterologous primary vaccination (ChAdOx1 followed by BNT162b2) showed a significantly higher median protective duration of 142 days. The results show that the total median protective duration of the first booster doses of COVID-19 vaccines was 57 days. ChAdOx1 batch code C1 was found to have the most extended protective duration of 173 days (range 163-192 days).
CONCLUSIONS
CONCLUSIONS
The current study revealed that the median protective duration of ChAdOx1 and BNT162b2 COVID-19 primary vaccination regimens administered in Saudi Arabia in 2021 was 134 days and that heterologous primary vaccination (ChAdOx1→BNT162b2) exhibited a significantly higher protective duration than other vaccination regimens.
Identifiants
pubmed: 36040662
doi: 10.1007/s40261-022-01195-x
pii: 10.1007/s40261-022-01195-x
pmc: PMC9425807
doi:
Substances chimiques
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-806Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa Abo El-Ella D, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524–40.
doi: 10.1080/07853890.2022.2031274
Alfaleh A, Alkattan A, Radwan N, Elzohri M, Alzaher A, Ibrahim M, et al. Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. Drugs Ther Perspect. 2022;38(2):84–92.
doi: 10.1007/s40267-022-00893-y
Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7(3):379–85.
doi: 10.1038/s41564-021-01053-0
Pascolo S. Vaccines against COVID-19: priority to mRNA-based formulations. Cells. 2021;10(10):2716.
doi: 10.3390/cells10102716
Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med. 2022;386(10):933–41.
doi: 10.1056/NEJMoa2117128
Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, Molbak K, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers: a Danish cohort study. MedRxiv. 2021. https://doi.org/10.1101/2021.03.08.21252200 .
doi: 10.1101/2021.03.08.21252200
Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831–7.
doi: 10.1038/s41591-022-01699-1
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–46.
doi: 10.1056/NEJMoa2119451
Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2022;386(2):116–27.
doi: 10.1056/NEJMoa2116063
Robles-Fontán MM, Nieves EG, Cardona-Gerena I, Irizarry RA. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico. Lancet Reg Health Am. 2022;9: 100212.
pubmed: 35229081
pmcid: 8867062
Saudi Center for Disease Prevention and Control (Saudi CDC). COVID-19 guidelines 2022. https://covid19.cdc.gov.sa/wp-content/uploads/2022/01/covid-19-coronavirus-disease-guidelines-en.pdf . Accessed 9 Aug 2022.
Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Pillai PS, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022;84(5):675–83.
doi: 10.1016/j.jinf.2021.12.044
Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. N Engl J Med. 2022;386(14):1375–7.
doi: 10.1056/NEJMc2200415
Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur. 2021;11: 100249.
doi: 10.1016/j.lanepe.2021.100249
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–85.
doi: 10.1056/NEJMoa2113017
Baum U, Poukka E, Palmu AA, Salo H, Lehtonen TO, Leino T. Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study. PLoS ONE. 2021;16(11): e0258704.
doi: 10.1371/journal.pone.0258704
Flacco ME, Soldato G, AcutiMartellucci C, Carota R, Di Luzio R, Caponetti A, et al. Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an Italian province. Vaccines (Basel). 2021;9(6):628.
doi: 10.3390/vaccines9060628
Bignucolo A, Scarabel L, Mezzalira S, Polesel J, Cecchin E, Toffoli G. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2021;9(8):825.
doi: 10.3390/vaccines9080825
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.
doi: 10.1038/nri.2016.90
Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–7.
doi: 10.1038/s41577-020-0348-8
Mauvais-Jarvis F, BaireyMerz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396(10250):565–82.
doi: 10.1016/S0140-6736(20)31561-0
Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22(7):1002–10.
doi: 10.1016/S1473-3099(22)00146-3
Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts. MedRxiv. 2021. https://doi.org/10.1101/2021.02.05.21251139 .
doi: 10.1101/2021.02.05.21251139
Uddin MN, Roni MA. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines (Basel). 2021;9(9):1033.
doi: 10.3390/vaccines9091033